Printer Friendly

MGI PHARMA EXPANDS BOARD

MGI PHARMA EXPANDS BOARD
 MINNEAPOLIS, Sept. 30 /PRNewswire/ -- MGI Pharma, Inc. (NASDAQ: MOGN), a specialty pharmaceutical company, announced that Hugh E. Miller has joined its board of directors.
 "We look forward to benefiting from Mr. Miller's many years of domestic and international pharmaceutical industry experience," said Kenneth F. Tempero, M.D., Ph.D., the company's chairman and chief executive officer. "His expertise in managing periods of corporate growth will serve us as well when we receive clearance from the Food and Drug Administration (FDA) to market Salagen(TM)."
 Miller was employed at ICI Pharmaceuticals (ICI) for many years where he held various positions in their domestic operations, including president of Stuart Pharmaceuticals and vice chairman and director of ICI Americas, Inc. During this period, he was a member of the governing board of the Pharmaceutical Manufacturers Association. Internationally, he managed ICI's marketing and manufacturing operations in Europe, the Middle East and Africa. He also served as chairman of a joint venture company in Japan and as a director of ICI Japan.
 Miller is a member of the board of directors and executive committees for the Wilmington Trust Company and the Medical Center of Delaware, Inc. He is a past director of the Diamond State Telephone Company.
 MGI Pharma acquires, develops and markets pharmaceuticals prescribed and recommended by physician specialists. Its initial focus is on developing products that improve the quality of life for critically and chronically ill patients. It currently sells DIDRONEL(R) I.V. Infusion and Oratect(TM) Gel to cancer specialists throughout the United States. The company is awaiting approval from the FDA for Salagen, a drug that treats the severe dry mouth resulting from radiation used to treat head and neck cancers. MGI Pharma has several additional products in various stages of clinical development.
 -0- 09/30/92
 CONTACT: Lori Weiman of MGI Pharma, 612-939-4666
 (MOGN) CO: MGI PHARMA, INC. IN: MTC SU: PER ST: MN -- MN002 -- X349 09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:324
Previous Article:LEADING EXECUTIVE SEARCH FIRM CHANGES NAME TO LAMALIE AMROP INTERNATIONAL
Next Article:IMM AND ACUITY DIGITAL, INC. ANNOUNCE MULTIYEAR AGREEMENTS
Topics:


Related Articles
MGI PHARMA ACQUIRES NEW CRITICAL CARE DRUG; MGI 330 COULD IMPROVE DIAGNOSIS OF HEART DISEASE AND RECOVERY FROM ISCHEMIA
MGI PHARMA'S SALAGEN(TM) DESIGNATED ORPHAN DRUG FOR SJOGREN'S SYNDROME
MGI PHARMA REPORTS 1992 RESULTS
MGI PHARMA REPORTS FIRST QUARTER 1993 RESULTS
MGI PHARMA, INC. APPOINTS NEW VICE PRESIDENT OF SALES AND MARKETING; COMMENTS ON SECOND QUARTER GROWTH
MGI PHARMA, INC. ANNOUNCES THAT ITS CHIEF EXECUTIVE OFFICER WILL RETIRE
CHARLES N. BLITZER APPOINTED PRESIDENT AND CEO OF MGI PHARMA, INC.
NATIONAL CANCER INSTITUTE VOTES FOR FUNDING OF CLINICAL TRIALS ON MGI PHARMA ACYLFULVENE COMPOUND
MGI PHARMA Announces Management Promotions and Elects New Board Member
MGI Pharma Updates Shareholders on Advancement of Cancer Therapy and Recent Product Launch at 1998 Annual Meeting

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters